Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.57 |
| ▸ | PPARA | Q07869 | 2/20 | 0.57 |
| ▸ | DHODH | Q02127 | 2/20 | 0.54 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | PLK1 | P53350 | 5/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.50 |
| ▸ | RARB | P10826 | 3/20 | 0.49 |
| ▸ | RARA | P10276 | 1/20 | 0.49 |
| ▸ | RARG | P13631 | 1/20 | 0.49 |
| ▸ | PLK3 | Q9H4B4 | 3/20 | 0.48 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL344535 | 0.99 | PPARA (0.59) | KAT8PPARADHODHPPARGPTPN1 | |
| SCHEMBL344421 | 0.99 | PPARA (0.59) | KAT8PPARADHODHPPARGPTPN1 | |
| SCHEMBL343983 | 0.96 | PTPN1 (0.54) | KAT8PPARADHODHPPARGPTPN1 | |
| SCHEMBL343405 | 0.90 | PTPN1 (0.57) | KAT8PPARADHODHPPARGPTPN1 | |
| SCHEMBL25223402 | 0.87 | PPARA (0.59) | KAT8PPARAPPARGPLK1RARB | |
| SCHEMBL12503256 | 0.86 | DHODH (0.59) | KAT8PPARADHODHPPARGPTPN1 | |
| SCHEMBL343997 | 0.85 | DHODH (0.56) | KAT8PPARADHODHPPARG | |
| SCHEMBL25253653 | 0.84 | KAT8 (0.67) | KAT8PPARADHODHPPARGPLK1 | |
| SCHEMBL12065209 | 0.84 | THRA (0.55) | KAT8PPARADHODHPPARGPLK1 | |
| SCHEMBL344375 | 0.84 | DHODH (0.55) | KAT8PPARADHODHPPARGPLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9714238-B2 | Therapeutic agents for ocular hypertension | ALLERGAN, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20160340347-A9 | THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION | ALLERGAN, INC. (US) | 2016-11-24 | — | — | US | disclosed |
| US-20150175586-A1 | THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION | ALLERGAN, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-8633220-B2 | Therapeutic agents for ocular hypertension | ALLERGAN, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20120015978-A1 | THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION | ALLERGAN, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2012003145-A2 | THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION | ALLERGAN, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175586-A1 | THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION | PTGIR, NHERF1, PTGS1 | KAT8 2848/4885PPARA 664/4885DHODH 1113/4885 |
| US-20160340347-A9 | THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION | PTGIR, NHERF1, PTGS1 | KAT8 2848/4885PPARA 664/4885DHODH 1113/4885 |
| US-20120015978-A1 | THERAPEUTIC AGENTS FOR OCULAR HYPERTENSION | PTGIR, NHERF1, PTGS1 | KAT8 2848/4885PPARA 664/4885DHODH 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.